Vanguard Fiduciary Trust
CMPX icon

Vanguard Fiduciary Trust’s Compass Therapeutics CMPX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
1,000,938
+2,798
+0.3% +$8.26K ﹤0.01% 2617
2026
Q1 		$5.28M Buy
+998,140
New +$5.76M ﹤0.01% 2052

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 94.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust's CMPX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Compass Therapeutics (CMPX) stake by 0.28% in Q2 2026, buying an estimated $8.26K and bringing the position to 1,000,938 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

Vanguard Fiduciary Trust first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.28M in Q1 2026. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Vanguard Fiduciary Trust held 1,000,938 shares of Compass Therapeutics worth $2.19M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 2,798 Compass Therapeutics shares in Q2 2026, an estimated $8.26K.
  • Compass Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2617 holding.
  • Vanguard Fiduciary Trust first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Compass Therapeutics position peaked at $5.28M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.